anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Hypertrophic scarring (HS) is a pathological condition characterized by excessive fibrosis and inflammation, resulting in excessive extracellular matrix formation in the skin. MIR155HG, a long non-coding RNA, is abnormally upregulated in fibrotic tissues; however, its underlying mechanism is poorly understood. Using single-cell sequencing data, we analyzed connective tissue growth factor (CTGF) expression in various cell types in HS and normal skin tissues and MIR155HG expression in clinical samples. To investigate the mechanism of fibrosis, an in vitro model using CTGF-treated hypertrophic scar fibroblasts (HSFBs) was established and qRT-PCR, western blotting and ELISA assays were performed to investigate the expression of interleukin (IL)-1β, IL-6, and mesenchymal markers α-smooth muscle actin (α-SMA). CTGF stimulates MIR155HG level through phosphorylated STAT3 binding to the MIR155HG promoter. We analyzed the methylation of MIR155HG, assessed the levels of miR-155-5p/-3p in CTGF-treated HSFBs and identified differentially expressed genes among HS and NS samples using the Gene Expression Omnibus RNA sequencing data. The binding between miR-155-5p/-3p and AZGP1 was confirmed using a dual-luciferase assay and inflammatory cytokine production and α-SMA expression were investigated in rescue experiments. The findings revealed that CTGF elevated inflammatory cytokine production, α-SMA and MIR155HG expression in HSFBs. MIR155HG is upregulated in HS tissues due to low DNA methylation. Mechanistically, miR-155-5p/-3p was directly bound to MIR155HG 3'UTR. MIR155HG silencing inhibited cytokine production and α-SMA expression by repressing the generation of miR-155-5p/-3p in CTGF-treated HSFBs. Bioinformatics analysis and luciferase reporter assays revealed that miR-155-5p/-3p targets AZGP1. In addition, transfection with plasmids carrying AZGP1 cDNA significantly inhibited the signaling activity of miR-155-5p/-3 p-overexpressing HSFBs. Our findings highlight the importance of the MIR155HG/miR-155/AZGP1 axis in regulating cytokine production and α-SMA in HS.
The invention belongs to the technical field of Chinese herbal medicines, and discloses a composition for adjuvant therapy of premature ejaculation and a preparation method thereof. The composition is suitable for adjuvant treatment of premature ejaculation, and is used in combination with psychotherapy and exercise therapy. The main reason is sweet in taste and warm in nature; the compatibility principle of the prescription is that the liver, kidney and spleen meridians are entered. Radix Dipsaci has effects of tonifying liver and kidney; the eucommia bark strengthens muscles and bones; the angelica dahurica dispels the wind and relieves the pain; galla chinensis can be used for arresting seminal emission and stopping enuresis; the lotus seeds tonify the kidney and nourish the heart; gordon euryale seed spleen invigorating and diarrhea relieving; radix Cyathulae is effective in promoting blood circulation and removing blood stasis; the Chinese prickly ash warms the middle warmer to relieve pain; cynomorium songaricum invigorates kidney and strengthens yang. The composition has effects in promoting blood circulation, strengthening muscle and tendon, stopping nocturnal emission, relieving premature ejaculation, prolonging life time, and improving essence and energy. Soaking the yellow wine to promote the absorption of the effective components in the yellow wine by all the raw materials; steaming, mixing all the effective components of the raw materials and part of yellow wine alcohol in the distillate. Decocting to further obtain residual effective components, thereby achieving the maximum utilization of raw materials.
The invention discloses stir-fried Semen Armeniacae Amarum. Northern mountain apricot kernels, also called Semen Armeniacae Amarum, are sweet and bitter in taste, mild and cold in nature and slightly toxic. According to record of Bencao Gangmu(Compendium of Materia Medica), Semen Armeniacae Amarum is mild in nature, bitter in taste, and thick in flavor as sour, bitter and salty flavor, functions in depressing qi primarily, acts on hand-Taiyin meridian and has efficacy of moistening lung, promoting digestion and dispelling stagnancy. Li shizhen said, Semen Armeniacae Amarum, which is capable of dispersing and depressing stagnated lung qi, can be applied to prepare medicines for dispelling pathogenic factors from muscles, dispelling wind, depressing qi, moistening dryness, promoting digestion and curing trauma, and its slight toxicity can be applied to wound healing and killing insects; thus, Semen Armeniacae Amarum is a medicinal and edible superior product with wide application scope. According to inspection and appraisal of the National food quality safety inspection and detection center, Semen Armeniacae Amarum is rich in unsaturated fatty acid, vitamin E, various microelements, carotene, ascorbic acid and amygdalin. The stir-fried Semen Armeniacae Amarum, prepared from wild organic high-quality Semen Armeniacae Amarum by combination of the conventional preparing process and the modern extraction technology, has efficacy of dispelling pathogenic factors from muscles, moistening lung and relieving a cough, is appetizing, crisp and rich in taste, is a healthcare product good for fitness, and accordingly is a high-end health and beauty snack for all groups of people.
Precision Spectra SCS System with CoverEdge Surgical Lead or more than 2 percutaneous leads. Subjects first received conventional single source programming followed by Precision Spectra SCS System advanced programming.
INTRODUCTION: APC-associated polyposis is a rare hereditary disorder characterized by the development of multiple adenomas in the digestive tract. Individuals with APC-associated polyposis need to be managed by specialized multidisciplinary teams in dedicated centers.
AREAS COVERED: The study aimed to review the literature on Familial adenomatous polyposis (FAP) to provide an update on diagnostic and surgical management while focusing on strategies to minimize the risk of desmoid-type fibromatosis, cancer in anorectal remnant, and postoperative complications. FAP individuals require a comprehensive approach that includes diagnosis, surveillance, preventive surgery, and addressing specific extracolonic concerns such as duodenal and desmoid tumors. Management should be personalized considering all factors: genotype, phenotype, and personal needs. Total colectomy and ileo-rectal anastomosis have been shown to yield superior QoL results when compared to Restorative Procto colectomy and ileopouch-anal anastomosis with acceptable oncological risk of developing cancer in the rectal stump if patients rigorously adhere to lifelong endoscopic surveillance. Additionally, a low-inflammatory diet may prevent adenomas and cancer by modulating systemic and tissue inflammatory indices.
EXPERT OPINION: FAP management requires a multidisciplinary and personalized approach. Integrating genetic advances, innovative surveillance techniques, and emerging therapeutic modalities will contribute to improving outcomes and quality of life for FAP individuals.
The invention relates to a preparation for restenosis prevention. The preparations for restenosis prevention known as yet do not reach sufficient active agent concentrations in the affected sections of the vascular walls as higher doses cause undesirable side effects. The present invention is a preparation to which at least one antihyperplastic agent is added that has a distribution ratio between butanol and water ≧0.5. The lipophilic active agent is absorbed by the vascular wall fast and in sufficient quantity. The preparation may be a liquid that can pass through capillaries and may contain a contrast agent so that the active agent is transferred into the vascular wall without any additional effort while the usually required contrast radiograms are taken. The preparation may also be applied to a catheter.
Randomized to receive Infasurf as the surfactant to treat respiratory distress syndrome. Doses 3ml/kg. to be repeated as needed by determination of attending neonatologist.
A system includes a processor circuit in communication with an intra-cavity imaging device. The processor circuit is configured to receive an intraluminal image obtained by an intraluminal imaging device when the intraluminal imaging device is located within a body lumen of a patient. The processor circuit also receives a user input selecting one location within the intra-lumen image and another user input selecting another location within the intra-lumen image. These two locations within the intra-lumen image define the boundaries of the intra-lumen image sector associated with the tissue type. The processor circuit determines an angle of a sector defined by the two locations. The visual representation of the intraluminal image and angle is displayed on a screen display.
PURPOSE:To obtain a pharmaceutical preparation for topical application, capable of stably keeping the medicine and easily controlling the amount of the medicine and effective in imparting sustained releasability to the product by supporting a medicine to a highly water-absorbing polymer. CONSTITUTION:A medicine is supported on a highly water-absorbing polymer having a water-absorption of preferably >=50mL, especially >=100mL based on 1g of the polymer. The amount of the medicine is usually 1mug to l g, preferably 100mug to 500mg based on 1g of the highly water-absorbing polymer. The highly water-absorbing polymer is selected from starch derivative, cellulosic polymer and synthetic polymer (especially synthetic polymer such as polyacrylic acid salt, polyvinyl alcohol, polyacrylamide or polyoxyethylene-based polymer). It can be used in the form of powder, film, nonwoven fabric, fiber, etc. The medicine to be used in the above process preferably takes solid state at normal temperature and is e.g. antibiotic antibacterial agent, antiviral agent, antimycotic agent, carcinostatic agent, antihistaminic agent, antirheumatic agent, gout treating agent, hormone preparation, cardiotonic agent, antiarrhythmic agent, agent for treating stenocardia and vasodilator.
PROBLEM TO BE SOLVED: To obtain the subject cosmetic which is free from problems on foul odor, discoloration, stability with time and skin irritation and has fine spread, feeling with freshness on use, high moisturizing effect and pliability effect by formulating reductive products of hydrocarbons contained in plant raw materials. SOLUTION: This cosmetic is obtained by formulating, as major components, reductive products of hydrocarbons, which are preferably composed of 25 to 30 carbon atoms and have molecular weights of 340-480 and boiling points of 390-490 deg.C, contained in at least one kind of plant raw materials selected from olive, soybean, amaranthaceous and palm seeds and rice bran. On this cosmetic, oily extracts from raw materials are blended in order to formulate reductive products of hydrocarbons. The oily extract extracted from raw materials is preferably used in order to formulate hydrocarbons in an amount of 90 wt.% or more and blended in an amount of 0.01-100 wt.%. As the type of cosmetic, e.g. various creams, emulsion and toilet water are illustrated.
BACKGROUND: Metabolic syndrome (MetS) is highly prevalent in individuals with schizophrenia (SZ), leading to negative consequences like premature mortality. Gut dysbiosis, which refers to an imbalance of the microbiota, and chronic inflammation are associated with both SZ and MetS. However, the relationship between gut dysbiosis, host immunological dysfunction, and SZ comorbid with MetS (SZ-MetS) remains unclear. This study aims to explore alterations in gut microbiota and their correlation with immune dysfunction in SZ-MetS, offering new insights into its pathogenesis.
METHODS AND RESULTS: We enrolled 114 Chinese patients with SZ-MetS and 111 age-matched healthy controls from Zhejiang, China, to investigate fecal microbiota using Illumina MiSeq sequencing targeting 16 S rRNA gene V3-V4 hypervariable regions. Host immune responses were assessed using the Bio-Plex Pro Human Cytokine 27-Plex Assay to examine cytokine profiles. In SZ-MetS, we observed decreased bacterial α-diversity and significant differences in β-diversity. LEfSe analysis identified enriched acetate-producing genera (Megamonas and Lactobacillus), and decreased butyrate-producing bacteria (Subdoligranulum, and Faecalibacterium) in SZ-MetS. These altered genera correlated with body mass index, the severity of symptoms (as measured by the Scale for Assessment of Positive Symptoms and Scale for Assessment of Negative Symptoms), and triglyceride levels. Altered bacterial metabolic pathways related to lipopolysaccharide biosynthesis, lipid metabolism, and various amino acid metabolism were also found. Additionally, SZ-MetS exhibited immunological dysfunction with increased pro-inflammatory cytokines, which correlated with the differential genera.
CONCLUSION: These findings suggested that gut microbiota dysbiosis and immune dysfunction play a vital role in SZ-MetS development, highlighting potential therapeutic approaches targeting the gut microbiota. While these therapies show promise, further mechanistic studies are needed to fully understand their efficacy and safety before clinical implementation.
This group will be randomly immersed in ice water (2°C temperature) for preset times and instructed to remove their hand if they cannot withstand these times. In total there will be 5 attempts with durations of 90, 60, 60, 60, 90 and 60 s respectively. Between dive attempts they will be instructed to put their arm on a towel and immediately do the arithmetic task of counting backwards from the number 2043 as quickly and accurately as they can. Each time they make a mistake in the mental task, they will be given negative feedback and must start again from the number 2043. The duration of the 4 arithmetic tasks (between each of the 5 immersion attempts) will be fixed at 45, 60, 90 and 45 s respectively.
Assessing communication abilities in patients with disorders of consciousness (DOCs) is challenging due to limitations in the behavioral scale. Electroencephalogram-based brain-computer interfaces (BCIs) and eye-tracking for detecting ocular changes can capture mental activities without requiring physical behaviors and thus may be a solution. This study proposes a hybrid BCI that integrates EEG and eye tracking to facilitate communication in patients with DOC. Specifically, the BCI presented a question and two randomly flashing answers (yes/no). The subjects were instructed to focus on an answer. A multimodal target recognition network (MTRN) is proposed to detect P300 potentials and eye-tracking responses (i.e., pupil constriction and gaze) and identify the target in real time. In the MTRN, the dual-stream feature extraction module with two independent multiscale convolutional neural networks extracts multiscale features from multimodal data. Then, the multimodal attention strategy adaptively extracts the most relevant information about the target from multimodal data. Finally, a prototype network is designed as a classifier to facilitate small-sample data classification. Ten healthy individuals, nine DOC patients and one LIS patient were included in this study. All healthy subjects achieved 100% accuracy. Five patients could communicate with our BCI, with 76.1±7.9% accuracy. Among them, two patients who were noncommunicative on the behavioral scale exhibited communication ability via our BCI. Additionally, we assessed the performance of unimodal BCIs and compared MTRNs with other methods. All the results suggested that our BCI can yield more sensitive outcomes than the CRS-R and can serve as a valuable communication tool.
FIELD: medicine. ^ SUBSTANCE: invention relates to field of cosmetology. Sprayed compositions, in particular, anhydrous aerosol compositions, contain active antiperspirant in form of particles. Antiperspirant basic composition, suitable for application together with propellent contains as moisturiser polyethylene glycol (PEG) with small molecular weight, in particular, PEG with molecular weight from 150 to 500. ^ EFFECT: invention ensures free antiperspirant spraying, elimination of clogging of aerosol packing nozzle. ^ 29 cl, 9 tbl, 16 ex
ABSTRACT OF THE DISCLOSURE         Disclosed is extracorporeal plasma perfusion over a therapeutic immobilized protein A (staphylococcal), SPA.          The perfused plasma is returned to the host or can be taken off one person and used to treat another and stored in perfused plasma banks.  Immobilized protein A quantities, volumes of plasma perfused and the rate of administration based on clinical and toxicity evaluations are set forth. A non-toxic drug infusion during the immediate postperfusion period obtains an observed tumoricidal response far exceeding those due to the extracorporeal plasma perfusion or drug infusion alone representing an in vivo synergism between the perfused plasma and the drug.  Also disclosed are the therapeutic protein A cartridge, its loading and delivery system, and a miniaturized immunoabsorbent apparatus enabling the processing of serum samples for testing small quanitities of plasma.         The government has rights in these inventions pursuant to U.S. Public Health Service Grants or Awards 5K04AI00302 and 5R01GM23517.
H:\amtJlnav<oeo\NRPobl\DCC\~ATS949~45_Ldoex-2/6/0H The invention provides improved methods for cell therapy. In particular, the invention provides therapeutic compositions of enhanced hematopoietic stem and progenitor cells having improved engraftment and homing properties, and methods of making the therapeutic compositions. The invention further provides methods of improving the efficacy of hematopoietic stem and progenitor cell transplantation including transplanting the therapeutic composition to subjects in need of hematopoietic system reconstitution. In addition to the tests discussed above, another important aspect of evaluating the final product is potency testing. Potency testing involves the quantitative measure of biological activity of a product. The biological activity should describe the ability of a product to achieve a defined biological effect. The biological activity measured should be closely related to the product's intended biological effect and ideally, it should be related to the product's clinical response [2-1_L]. Measurement of the potency of a product is not the same as measuring clinical efficacy. Rather, it is a means to control product quality. Potency assays for cellular products usually take a considerable amount of time to develop. Generally, the development of potency assays is progressive and begins during preclinical and early clinical development. A potency assay should be validated and already in place prior to phase III clinical trials involving a specific cellular therapy [9, 1].
Long-term clinical trials have been conducted with dosages up to 200 mg of bicalutamide daily and these dosages have been well tolerated. A single dose of bicalutamide that results in symptoms of an overdose considered to be life threatening has not been established. 

There is no specific antidote; treatment of an overdose should be symptomatic. 

In the management of an overdose with bicalutamide, vomiting may be induced if the patient is alert. It should be remembered that, in this patient population, multiple drugs may have been taken. Dialysis is not likely to be helpful since bicalutamide is highly protein bound and is extensively metabolized. General supportive care, including frequent monitoring of vital signs and close observation of the patient, is indicated.
Disruption of corticospinal tracts (CST) is a leading factor for motor impairments following intracerebral hemorrhage (ICH) in the striatum. Previous studies have shown that therapeutic hypothermia (HT) improves outcomes of ICH patients. However, whether HT has a direct protection effect on the CST integrity and the underlying mechanisms remain largely unknown. In this study, we employed a chemogenetics approach to selectively activate bilateral warm-sensitive neurons in the preoptic areas to induce a hypothermia-like state. We then assessed effects of HT treatment on the integrity of CST and motor functional recovery after ICH. Our results showed that HT treatment significantly alleviated axonal degeneration around the hematoma and the CST axons at remote midbrain region, ultimately promoted skilled motor function recovery. Anterograde and retrograde tracing revealed that HT treatment protected the integrity of the CST over an extended period. Mechanistically, HT treatment prevented mitochondrial swelling in degenerated axons around the hematoma, alleviated mitochondrial impairment by reducing mitochondrial ROS accumulation and improving mitochondrial membrane potential in primarily cultured cortical neurons with oxyhemoglobin treatment. Serving as a proof of principle, our study provided novel insights into the application of HT to improve functional recovery after ICH.
A high volume of patients are admitted to hospitals yearly for bowel obstruction/ileus complications. Lifetime risk of small bowel obstruction varies from 0.1%-5% if patients have not undergone abdominal surgery, but increases to 30% if the patient underwent a prior abdominal surgery. Ileus is also a common complication in the short term post-operative period. Both of these conditions are initially treated with nasogastric tube decompression if the patient is having emesis.

The investigators were unable to find any literature that shows a concrete volume of nasogastric tube output that was deemed the maximum for safe removal. Signs of return of bowel function can indicate it is safe to remove the nasogastric tube. These include flatus, bowel movements, decrease in nasogastric tube output amount, change of nasogastric tube output color from bilious (green) to more gastric (yellow) or salivary (clear/foamy) quality. Some physicians prefer to perform a clamp trial before removal of the nasogastric tube. The duration of the trial and cutoff amount of residual drainage varies among physicians. Regardless of the duration, the nasogastric tube is essentially stenting open the lower esophageal sphincter while it is left in place and not connected to suction. This, theoretically, places the patient at risk for aspiration and subsequent pneumonia. Information in the literature appears divided in regard to aspiration risk.

This study hopefully will support the statement that it is safe to remove the nasogastric tube with signs of bowel function, without the need for clamp trials and thus avoiding any possible adverse outcomes associated with the trial. The investigators also anticipate that this study will provide objective guidelines on which patients will continue to improve after nasogastric tube removal.
Forty women (range 25-75 years), with a class I and II RA diagnosis according to the American Rheumatism Association's 1987 revised criteria, were recruited from a university hospital's rheumatology clinic. Exclusion criteria included the presence of any cardiovascular, neuromuscular and metabolic diseases or severe limitations in mobility. Five patients were excluded for not attending the inclusion criteria, leading to a final number of 35 RA patients.